Merck’s Vaxneuvance
As you likely know, Merck has launched a new pneumococcal vaccine, Vaxneuvance (PCV15), that is FDA approved and ACIP recommended for both children and adults. CPP members now have a choice between Prevnar 13 (Pfizer) or Vaxneuvance (Merck) for pediatric patients (2, 4, 6 and 12-15 months) and a choice between Prevnar 20 (Pfizer) or Vaxneuvance + Pneumovax 23 (Merck) for adult patients (65+).
We have been told that most private payers are paying for this new CPT code (90671) and most state VFC programs added Vaxneuvance. We recommend reaching out to your major payers and your state’s VFC program to verify for your practice.